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16Research articleGonadotropin-releasing hormone type II 
antagonist induces apoptosis in MCF-7 and 
triple-negative MDA-MB-231 human breast cancer 
cells in vitro and in vivo
Carsten Gründker*, Crispin Föst, Stefanie Fister, Nadine Nolte, Andreas R Günthert and Günter Emons
Abstract
Introduction: Triple-negative breast cancer does not express estrogen and progesterone receptors, and no 
overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of 
specific therapies that target these receptors. Today chemotherapy is the only systematic therapy for patients with 
triple-negative breast cancer. About 50% to 64% of human breast cancers express receptors for gonadotropin-
releasing hormone (GnRH), which might be used as a target. New targeted therapies are warranted. Recently, we 
showed that antagonists of gonadotropin-releasing hormone type II (GnRH-II) induce apoptosis in human endometrial 
and ovarian cancer cells in vitro and in vivo. This was mediated through activation of stress-induced mitogen-activated 
protein kinases (MAPKs) p38 and c-Jun N-terminal kinase (JNK), followed by activation of proapoptotic protein Bax, loss 
of mitochondrial membrane potential, and activation of caspase-3. In the present study, we analyzed whether GnRH-II 
antagonists induce apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells that express GnRH 
receptors. In addition, we ascertained whether knockdown of GnRH-I receptor expression affects GnRH-II antagonist-
induced apoptosis and apoptotic signaling.
Methods: Induction of apoptosis was analyzed by measurement of the loss of mitochondrial membrane potential. 
Apoptotic signaling was measured with quantification of activated MAPK p38 and caspase-3 by using the Western blot 
technique. GnRH-I receptor protein expression was inhibited by using the antisense knockdown technique. In vivo 
experiments were performed by using nude mice bearing xenografted human breast tumors.
Results: We showed that treatment of MCF-7 and triple-negative MDA-MB-231 human breast cancer cells with a 
GnRH-II antagonist results in apoptotic cell death in vitro via activation of stress-activated MAPK p38 and loss of 
mitochondrial membrane potential. In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in 
MDA-MB-231 human breast cancer cells. After knockdown of GnRH-I receptor expression, GnRH-II antagonist-induced 
apoptosis and apoptotic signaling was only slightly reduced, indicating that an additional pathway mediating the 
effects of GnRH-II antagonists may exist. The GnRH-I receptor seems not to be the only target of GnRH-II antagonists. 
The antitumor effects of the GnRH-II antagonist could be confirmed in nude mice. The GnRH-II antagonist inhibited the 
growth of xenotransplants of human breast cancers in nude mice completely, without any apparent side effects.
Conclusions: GnRH-II antagonists seem to be suitable drugs for an efficacious and less-toxic endocrine therapy for 
breast cancers, including triple-negative breast cancers.
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Breast cancer is the most frequent malignant disease in
women, with more than 1,000,000 new cases and 370,000
deaths yearly worldwide [1]. About 75$ to 80% of breast
cancers are hormone-receptor positive and express estro-
gen and progesterone receptors [2,3]. Approximately 15%
to 20% of breast cancers overexpress/amplify the HER2-
neu gene, with about half of these co-expressing steroid-
hormone receptors. For patients with hormone-receptor-
positive or HER2-neu-positive tumors, effective targeted
therapies have been developed. About 10% to 15% of
breast cancers do not express either estrogen and proges-
terone receptor and also do not overexpress/amplify the
HER2-neu gene [4-6]. These so-called triple-negative
breast cancers lack the benefits of specific therapies that
target these receptors. Triple-negative breast cancer is
relatively chemosensitive to conventional cytotoxic
agents such as cisplatin, but the effectiveness is for only a
short duration. Therefore, the development of new thera-
pies is of great interest.
The expression of gonadotropin-releasing hormone
(GnRH-I) and its receptor as a part of a negative auto-
crine/paracrine regulatory mechanism of cell prolifera-
tion has been demonstrated in a number of malignant
tumors, including cancers of endometrium, ovary, and
breast [7]. In these cancers, the in vitro proliferation can
be inhibited by agonistic analogues of GnRH-I in a dose-
and time-dependent manner [7-11]. GnRH-I antagonists
also have marked antiproliferative activity in most endo-
metrial, ovarian, and breast cancer cell lines tested in
vitro, indicating that the dichotomy of GnRH agonists
and antagonists might not apply to the GnRH system in
cancer cells [7-11].
Besides GnRH-I, a second structural variant of GnRH
exists in mammals. GnRH-II is totally conserved in struc-
ture from fish to mammals. It differs from GnRH-I in
three amino acids. GnRH-II receptor was found in differ-
ent species, including nonhuman primates. Its existence
in the human is controversial. Several lines of evidence,
however, exist for a functional GnRH-II receptor [12].
GnRH-II has antiproliferative effects on human endome-
trial, ovarian, and breast cancer cells that are significantly
greater than those of the superactive GnRH-I agonist
triptorelin [13]. Induction of apoptosis is not involved in
the downregulation of cancer cell proliferation induced
by agonists of GnRH-I or GnRH-II [7]. GnRH-I and
GnRH-II agonists rather inhibit mitogenic signal trans-
duction of growth-factor receptors via activation of a
phosphotyrosine phosphatase, resulting in downregula-
tion of cancer cell proliferation [14-16].
Recently, we showed that antagonistic analogues of
GnRH-II induced apoptotic cell death in human endome-
trial and ovarian cancer cells in vitro, via dose-dependent
loss of mitochondrial membrane potential and activation
of caspase-3 [17]. These antitumor effects could be con-
firmed in nude mice. GnRH-II antagonists significantly
inhibited the growth of xenotransplants of human endo-
metrial and ovarian cancers in nude mice, without any
apparent side effects [17]. Apoptosis induced by GnRH-II
antagonists is mediated through the intrinsic apoptotic
pathway via stress-induced MAPKs p38- and JNK-
induced activation of the pro-apoptotic protein Bax, loss
of mitochondrial membrane potential, release of cyto-
chrome c, and activation of caspase-3 [17,18]. In addition,
we demonstrated that GnRH-II antagonists couple to the
GnRH-I receptor and have binding affinities to the
GnRH-I receptor similar to those of the GnRH-I antago-
nist cetrorelix [18]. Furthermore, we showed that [D-Lys6
]-GnRH-II is an agonist at the GnRH-I receptor, whereas
GnRH-II antagonists are clear antagonists at the GnRH-I
receptor [18].
About 50% to 64% of human breast cancers express
GnRH-I receptors [19-22]. Because GnRH-II antagonists
appear to be suitable drugs for efficacious and less-toxic
endocrine therapy for endometrial and ovarian cancers,
the question arises whether GnRH-II antagonist treat-
ment could also be a new therapeutic option for breast
cancers. Especially for triple-negative breast cancers,
defined by the lack of both estrogen and progesterone
receptors, as well as a lack of overexpression/amplifica-
tion of the HER2-neu gene, the therapeutic options today
are very limited.
In the present study, we analyzed whether a GnRH-II
antagonist induces apoptosis in estrogen receptor/pro-
gesterone receptor-positive MCF-7 human breast cancer
cells, which have a normal expression of HER2-neu and
triple-negative MDA-MB-231 human breast cancer cells
in vitro and in vivo. In addition, we ascertained whether
knockdown of GnRH-I receptor expression affects
GnRH-II antagonist-induced apoptosis, measured by loss
of mitochondrial membrane potential and GnRH-II
antagonist-induced apoptotic signaling, analyzed by acti-
vation of stress-activated MAPK p38 and caspase-3.
Materials and methods
Cell lines and culture conditions
The human breast cancer cell lines MCF-7 and MDA-
MB-231 (triple-negative) were obtained from American
Type Culture Collection (ATCC, Manassas, Virginia). To
guarantee the identity of the cell lines over the years, the
cells were expanded after purchase, and aliquots were
stored in liquid nitrogen. Every half year, a new frozen
stock was opened and expanded to carry out the experi-
ments. The cells were cultured at 37°C in a humidified
atmosphere of 5% CO2 in air, as previously described [8-
10].
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Female athymic (nude) mice (CD1 nu/nu), 6 to 8 weeks
old on arrival, were obtained from Charles River
(Sulzfeld, Germany). The mice were housed in sterile
cages in a temperature-controlled room with a 12-h light/
12-h dark schedule and were fed autoclaved chow and
water ad libitum. All experiments were done according to
the German ethical guidelines and the German laws for
protection of animals and were approved by the Lower
Saxony State Office for Consumer Protection and Food
Safety, Department for Animal Protection, Oldenburg,
Germany.
GnRH analogues
The GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2, D-3Pal3,6,
Leu8, D-Ala10]GnRH-II was developed by us and synthe-
sized by Peptide Specialty Laboratories GmbH (Heidel-
berg, Germany) [17]. The GnRH-I agonist [D-Trp6]GnRH
(triptorelin) was kindly provided by Ferring Pharmaceuti-
cals (Copenhagen, Denmark).
GnRH-I receptor knockdown
GnRH-I receptor knockdown was conducted as
described previously [23]. A 43-bp fragment of the
human GnRH-I receptor cDNA was cloned in antisense
orientation (5'-CT AGA ACC ATG GAC TGT CCG ACT
TTG CTG TTG CTT TTC AAA GC-3') into the NheI/
SalI sites of the eukaryotic expression vector, pIRES
(Clontech, Palo Alto, California, USA), to produce the
pGnRH-IR-antisense vector. Cells were grown to approx-
imately 50% confluence on Nunc two-well chamber slides
(immune cytochemistry) or in Nunc 100-mm dishes
(immunoblotting). Transfections were done by using
Superfect liposome reagents and following the manufac-
turer's instructions (Qiagen). After 12 h, transfected cells
and nontransfected control cells were treated with the
GnRH-I agonist triptorelin (100 nM) to induce GnRH-I
receptor protein internalization. Twelve hours later, the
medium was changed, and 20 ml PBS-BSA or an appro-
priate dilution of the GnRH-II antagonist [Ac-D2Nal1, D-
4Cpa2, D-3Pal3,6, Leu8, D-Ala10]GnRH-II was added, to a
final concentration of 10-7 M. Every 12 h, fresh PBS-BSA
or GnRH-II antagonist was added. After 24 h of incuba-
tion, the medium was changed.
Knockdown of the GnRH-I receptor protein was evalu-
ated with immune cytochemistry by using a monoclonal
mouse anti-human GnRH-I receptor antibody (clone
A9E4; Research Diagnostics, Flanders, NJ, USA) and
immunoblotting by using a polyclonal rabbit antihuman
GnRH-I receptor antiserum (Peptide Research Laborato-
ries, Heidelberg, Germany), as described previously [23].
Mitochondrial membrane potential
For determination of GnRH-II antagonist-induced loss of
mitochondrial membrane potential, cells with and with-
out GnRH-I receptor knockdown were treated without or
with the GnRH-II antagonist (10-9 and 10-7 M) for 72 h.
After incubation, the cells were washed with PBS once,
and the mitochondrial membrane potential was detected
by using the JC-1 mitochondrial membrane potential
detection kit, according the instructions of the manufac-
turer (Biotium, Hayward, CA, USA).
Western blot analysis
GnRH-II antagonist-induced activation of stress-acti-
vated MAPK p38 and of caspase-3 was analyzed with
Western blot.
Polyclonal rabbit anti-human phospho-p38 and poly-
clonal rabbit anti-human p38 antibodies were obtained
from Cell Signaling (Frankfurt/Main, Germany). Poly-
clonal rabbit anti-human active caspase-3 antibody was
purchased from BD Pharmingen (Heidelberg, Germany),
and polyclonal anti human β-actin antibody was from
Sigma Aldrich (Deisenhofen, Germany).
For determination of GnRH-II antagonist-induced p38
activity, cells with (wild-type; WT) and without GnRH-I-
receptor expression (GnRH-I receptor knockdown, KD)
were treated without or with the GnRH-II antagonist (10-
7 M) for 45 min. For determination of GnRH-II antago-
nist-induced caspase-3 activity, cells with (wild-type;
WT) and without GnRH-I-receptor expression (GnRH-I-
receptor knockdown; KD) were treated without or with
the GnRH-II antagonist (10-9 M and 10-7 M) for 48 h.
After incubation, cells were detached immediately with
0.5 g trypsin (Biochrom, Berlin, Germany) and 5 mmol
EDTA in 1 l PBS/BSA. The pellets were washed twice
with PBS and resuspended with CelLytic buffer (Sigma)
containing protease inhibitors (Sigma). Equal amounts of
protein per sample (40 μg) were used and diluted to equal
volumes with Laemmli buffer. The cell lysates were sepa-
rated on SDS-PAGE (10%, ProSieve 50 Gel Solution;
Cambrex, Verviers, Belgium) under reducing conditions
and transferred to nitrocellulose membranes (Hybond-
ECL; GE Healthcare Europe, Munich, Germany). The
nitrocellulose membranes were blocked with 5% instant
skimmed-milk powder, spray-dried (Naturaflor; Töpfer
GmbH, Dietmannsried, Germany) in TBST (137 mM
NaCl, 2.7 mM KCL, 0.1% Tween 20, 25 mM Tris/Cl, pH
7.4) for 1 h at RT, washed with TBST, and then incubated
at 4°C overnight with the appropriate antibody in an
1:500 (anti β-Actin) or a 1:1,000 dilution in TBST, and
then, after washings, incubated at RT with horseradish
peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG
(GE Healthcare Europe) at an 1:10,000 dilution in TBST
for 1 h. After washings, specifically bound antibody was
detected by using the enhanced chemiluminescence kit
(ECL; Millipore, Schwalbach, Germany). The bands were
analyzed by using the Kodak 1D image system (Kodak,
New Haven, CT, USA).
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Tumors were initiated by subcutaneous injection of 1 ×
107 cancer cells into the right flank of female athymic
(nude) mice (CD1 nu/nu). After 2 (MDA-MB-231) or 3
(MCF-7) weeks, all animals had developed solid tumors
of about 200 mm3, and treatment was initiated. The in
vivo experiments were done as follows: vehicle solution
(control 1), 25 nmol of GnRH-I agonist triptorelin (con-
trol 2), or 25 nmol of GnRH-II antagonist per mouse (five
mice per group) was injected intraperitoneally. Treatment
was repeated every 2 days. Tumor volumes were mea-
sured on days 7, 11, 16, and 21 of treatment (MCF-7) or
on days 4, 8, 12, and 16 of treatment (MDA-MB-231).
The mice were killed after 21 (MCF-7) or 16 (MDA-MB-
231) days.
Statistical analysis
All experiments were repeated 3 times with different pas-
sages of the respective cell lines. The data were tested for
significant differences with one-way analysis of variance
followed by the Student-Newman-Keuls test for compari-
son of individual groups, after a Bartlett test had shown
that variances were homogeneous.
Results
Effects of GnRH-II antagonist treatment on induction of 
apoptosis in MCF-7 and triple-negative MDA-MB-231 
human breast cancer cells in vitro 
To analyze the effects of GnRH-II antagonist treatment
on induction of apoptosis in estrogen receptor/progester-
one receptor-positive MCF-7 human breast cancer cells,
which have a normal expression of HER1-neu and triple-
negative MDA-MB-231 human breast cancer cells,
GnRH-II antagonist-induced loss of mitochondrial mem-
brane potential (ΔΨ) was measured (Figure 1a). Treat-
ment of MCF-7 and triple-negative MDA-MB-231 breast
cancer cells with cytotoxic agent doxorubicin (10-9 M;
positive control) or with the GnRH-II antagonist (10-9
and 10-7 M) for 72 h resulted in a reduction of mitochon-
drial membrane potential. After treatment with 10-7 M
doxorubicin (DOX; positive control), mitochondrial
membrane potential was decreased to 72.28 ± 3.98% of
control (MCF-7; P < 0.01 versus control; Figure 1b) or to
76.49 ± 4.15% of control (MDA-MB-231; P < 0.01 versus
control; not shown). Treatment with 10-9 M GnRH-II
antagonist resulted in a decrease of mitochondrial mem-
brane potential to 64.51 ± 6.95% of control (MCF-7; P <
0.001; Figure 1a) or to 67.23 ± 4.32% of control (MDA-
MB-231; P < 0.001 versus control; not shown). After
treatment with 10-7 M GnRH-II antagonist, the mito-
chondrial membrane potential was reduced to 47.94 ±
6.14% of control (MCF-7; P < 0.001 versus control; Figure
1a) or to 52.46 ± 3.37% of control (MDA-MB-231; P <
0.001 versus control; not shown).
Effects of GnRH-II antagonist treatment on induction of 
apoptosis in MCF-7 and MDA-MB-231 human breast cancer 
cells in vitro after knockdown of GnRH-I receptor 
expression
To analyze whether the effects of the GnRH-II antagonist
are mediated through the GnRH-I receptor, the expres-
sion of GnRH-I receptor protein was inhibited by using
the antisense knockdown technique.
A 43-bp cDNA encoding a fragment of the human
GnRH-I receptor was cloned in antisense orientation into
the NheI/SalI sites of the eukaryotic expression vector
pIRES, to produce the pGnRH-I-R-antisense vector.
Knockdown of the GnRH-I receptor protein was demon-
strated with immune cytochemistry by using a monoclo-
nal mouse anti-human GnRH-I receptor antibody (Figure
1b-d) and immunoblotting by using a polyclonal rabbit
antihuman GnRH-I receptor antiserum (not shown; c.f.
[23]). After internalization of the GnRH-I receptor
induced by GnRH-I agonist triptorelin, a high density of
novel synthesis of GnRH-I receptor protein, seen as
GnRH-I receptor antigenicity, could be observed in non-
transfected cells (Figure 1c), whereas transfected cells
showed only slight GnRH-I receptor antigenicity (Figure
1d). As early as 1 day after knockdown of GnRH-I recep-
tor expression, GnRH-I receptor protein antigenicity was
significantly reduced in comparison with the control.
After 2 days, no more GnRH-I receptor protein could be
detected; however, 4 days later, a slight GnRH-I receptor
protein antigenicity could be observed, indicating that
the effectiveness of GnRH-I receptor knockdown begins
to decrease after 6 days (not shown; c.f. [23]).
To analyze the effects of GnRH-II antagonist treatment
on induction of apoptosis in GnRH-I receptor-negative
(GnRH-I receptor knockdown) human breast cancer cells
in comparison with the GnRH-I receptor-positive (wild-
type) human breast cancer cells, GnRH-II antagonist-
induced loss of mitochondrial membrane potential (ΔΨ)
was measured (Figure 1a). After knockdown of GnRH-I
receptor expression, GnRH-II antagonist-induced
decrease of mitochondrial membrane potential was
slightly reduced, as compared with the effect of GnRH-II
antagonist treatment in nontransfected cells. Treatment
of the GnRH-I receptor knockdown cell lines with 10-9 M
GnRH-II antagonist resulted in a decrease of mitochon-
drial membrane potential to 75.35 ± 4.64% of control
(MCF-7; P < 0.01 versus control; not significant versus
WT; Figure 1a) or to 78.26 ± 3.47% of control (MDA-MB-
231; P < 0.01 versus control; not significant versus WT;
not shown). After treatment of the GnRH-I receptor
knockdown cell lines with 10-7 M GnRH-II antagonist,
mitochondrial membrane potential was reduced to 61.92
± 5.27% of control (MCF-7; P < 0.001 versus control; not
significant versus WT; Figure 1a) or to 64.93 ± 4.53% of
Gründker et al. Breast Cancer Research 2010, 12:R49
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nificant versus WT; not shown).
Effects of GnRH-II antagonist treatment on apoptotic 
signaling in MCF-7 and MDA-MB-231 human breast cancer 
cells in vitro 
To analyze the effects of GnRH-II antagonist treatment
on apoptotic signaling, GnRH-II antagonist-induced acti-
vation of stress activated MAPK p38 (Figure 2a) and cas-
pase-3 (Figure 2b) in MCF-7 and MDA-MB-231 human
breast cancer cells was measured.
Activation of p38 was considerably increased after
GnRH-II antagonist treatment (Figure 2a, third band) as
compared with the untreated control (Figure 2a, first
band). The effects of the GnRH-II antagonist on induc-
tion of apoptotic cell death could further be confirmed by
measurement of caspase-3 activity. Treatment of MDA-
MB-231 human breast cancer cells with cytotoxic agent
doxorubicin (10-9 M; positive control) or with of the
GnRH-II antagonist (10-9 and 10-7 M) for 48 h resulted in
increased caspase-3 activity (Figure 2b). After treatment
with 10-9 M doxorubicin (positive control), caspase-3
activity was increased to 168.8 ± 17.54% of control
(MDA-MB-231; P < 0.05; Figure 2b). Treatment with 10-9
M GnRH-II antagonist resulted in an increase of caspase-
3 activity to 195.8 ± 12.32% of control (MDA-MB-231; P
< 0.01). After treatment with 10-7 M GnRH-II antagonist,
caspase-3 activity was increased to 279.8 ± 25.38% of
control (MDA-MB-231; P < 0.001). MCF-7 human breast
cancer cells are caspase-3 deficient. Therefore, no cas-
pase-3 activation was detectable.
Figure 1 Effects of GnRH-II antagonist treatment on induction of apoptosis in GnRH-I receptor-positive (wild-type; WT) and GnRH-I recep-
tor-negative (GnRH-I receptor knockdown; KD) MCF-7 human breast cancer cells in vitro. (a) Percentage of mitochondrial membrane potential 
(ΔΨ) after 72 h of treatment of GnRH-I receptor-positive (wild-type; WT) and GnRH-I receptor-negative (GnRH-I receptor knockdown; KD) MCF-7 breast 
cancer cells without (control = 100%) or with cytotoxic agent doxorubicin (10-9 M; positive control) or with GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2, 
D-3Pal3, D-Lys6, D-Ala10]GnRH-II (10-7 M and 10-9 M). Columns represent mean ± SEM of data obtained from three independent experiments in three 
different passages of the cell line. (a) P < 0.001 versus control; (b)P < 0.01 versus control. Experiments using MDA-MB-231 human breast cancer cells 
gave identical results. (b-d) Immune histochemical detection of GnRH-I receptor protein by using a monoclonal mouse anti-human GnRH-I receptor 
antibody. (b) Control performed by omission of the primary antibody. (c) Nontransfected cells. (d) Cells transfected with pGnRH-I-R antisense expres-
sion vector.
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signaling in MCF-7 and MDA-MB-231 human breast cancer 
cells in vitro after knockdown of GnRH-I receptor 
expression
To analyze the effects of GnRH-II antagonist treatment
on apoptotic signaling in GnRH-I receptor-negative
(GnRH-I receptor knockdown) human breast cancer cells
in comparison to the GnRH-I receptor-positive (wild-
type) human breast cancer cells, we measured the GnRH-
II antagonist-induced activation of stress activated
MAPK p38 (Figure 2a) in GnRH-I receptor-negative
(GnRH-I receptor knockdown) MCF-7 and MDA-MB-
231 human breast cancer cells (Figure 2a). Effects of
GnRH-I receptor knockdown on caspase-3 activation
were analyzed in GnRH-I receptor-negative (GnRH-I
receptor knockdown) MDA-MB-231 human breast can-
cer cells (Figure 2b). After knockdown of GnRH-I recep-
tor expression, GnRH-II antagonist-induced activation of
p38 was slightly reduced (Figure 2a, fourth band), as com-
pared with the effect of GnRH-II antagonist treatment in
nontransfected cells (Figure 2a, third band). The basal
amount of phosphorylated p38 after knockdown of
GnRH-I receptor expression alone (Figure 2a, second
band) was only slightly decreased or nearly the same as
compared with that in nontransfected cells without
GnRH-II antagonist treatment (Figure 2a, first band).
After knockdown of GnRH-I receptor expression, GnRH-
II antagonist-induced caspase-3 activation was slightly
reduced as compared with the effect of GnRH-II antago-
nist treatment in nontransfected cells. Treatment of the
GnRH-I receptor knockdown cell lines with 10-9 M
GnRH-II antagonist resulted in an increase of caspase-3
activity to 170.6 ± 11.71% of control (MDA-MB-231; P <
0.05 versus control; not significant versus WT; Figure 2b).
After treatment of the GnRH-I receptor knockdown cell
lines with 10-7 M GnRH-II antagonist, caspase-3 activity
was increased to 254.5 ± 26.8% of control (MDA-MB-
231; P < 0.01 versus control; not significant versus WT;
Figure 2b).
Effects of GnRH-II antagonist treatment on tumor growth in 
vivo 
To show the proof-of-principle of an anti-tumor therapy
using GnRH-II antagonists, nude mice bearing xeno-
grafted human breast tumors were treated subcutane-
ously with the GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2,
D-3Pal3,6, Leu8, D-Ala10]GnRH-II.
Female nude mice bearing MCF-7 (Figure 3a) or triple-
negative MDA-MB-231 (Figure 3b) tumors s.c. were
treated without (control 1) or with 25 nmol per injection
of GnRH-I agonist triptorelin (control 2) or with 25 nmol
per injection of the GnRH-II antagonist. The treatments
were repeated every 2 days. The mice were killed after 16
(MDA-MB-231) or 21 (MCF-7) days of treatment. The
increase of the tumor volume of the mice receiving ther-
apy with GnRH-II antagonists was lower than that with
the control animals. After 7 days of treatment, the differ-
ences on MCF-7 tumor growth (Figure 3a) became highly
significant (P < 0.001) and remained highly significant (P
< 0.001). The differences in MDA-MB-231 tumor growth
(Figure 3b) became significant (P < 0.5) after 4 days of
Figure 2 Effects of GnRH-II antagonist treatment on apoptotic 
signaling in GnRH-I receptor-positive (wild-type; WT) and GnRH-I 
receptor-negative (GnRH-I receptor knockdown; KD) human 
breast cancer cells in vitro. (a) Amount of phosphorylated p38 after 
treatment without or with GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2, D-
3Pal3,6, Leu8, D-Ala10]GnRH-II (10-7 M) in nontransfected MCF-7 breast 
cancer cells and in MCF-7 breast cancer cells after knockdown of 
GnRH-I receptor expression. These are representative data obtained 
from three independent experiments in three different passages of the 
cell line. Experiments using MDA-MB-231 human breast cancer cells 
gave identical results. (b) Percentage of caspase-3 activity after 48 h of 
treatment of GnRH-I receptor-positive (wild-type; WT) and GnRH-I re-
ceptor-negative (GnRH-I receptor knockdown; KD) MDA-MB-231 
breast cancer cells without (control = 100%) or with cytotoxic agent 
doxorubicin (10-9 M; positive control) or with GnRH-II antagonist [Ac-
D2Nal1, D-4Cpa2, D-3Pal3, D-Lys6, D-Ala10]GnRH-II (10-7 M and 10-9 M). 
Columns represent mean ± SEM of data obtained from three indepen-
dent experiments in three different passages of the cell line. (a) P < 
0.001 versus control; (b) P < 0.01 versus control; (c) P < 0.05 versus con-
trol.
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nificant (P < 0.001) and remained highly significant (P <
0.001). Side effects were not observed. To exclude that the
antitumor effects of the GnRH-II antagonist are due to an
interaction with the pituitary GnRH receptors, a second
control group (control 2) was treated with 25 nmol per
injection of the GnRH-I agonist triptorelin. The increase
of the tumor volume of the mice receiving therapy with
GnRH-I agonist triptorelin was nearly the same as that
with the animals of control 1. No antitumor effects were
observed with triptorelin.
Discussion
Previous work showed that nanomolar concentrations of
GnRH-II antagonists induce apoptotic cell death in
human endometrial and ovarian cancer cells in vitro and
in vivo [17]. In addition, we showed that apoptosis
induced by GnRH-II antagonists is mediated through the
intrinsic apoptotic pathway via stress-induced MAPKs
p38- and JNK-induced activation of the proapoptotic
protein Bax, loss of mitochondrial membrane potential,
release of cytochrome c, and activation of caspase-3
[17,18]. Furthermore, we demonstrated that GnRH-II
antagonists bind to the GnRH-I receptor and are clear
antagonists at the GnRH-I receptor [18].
In the present study, we showed that treatment of estro-
gen receptor/progesterone receptor-positive MCF-7 and
triple-negative MDA-MB-231 human breast cancer cells
with the GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2, D-
3Pal3,6, Leu8, D-Ala10]GnRH-II resulted in apoptotic cell
death via activation of stress-activated MAPK p38 and
loss of mitochondrial membrane potential. In addition,
GnRH-II antagonist-induced activation of caspase-3
could be observed in MDA-MB-231 human breast cancer
cells. MCF-7 human breast cancer cells are caspase-3
deficient [24]. Therefore, no caspase-3 activation was
detectable. Apoptotic signaling in MCF-7 cells differs
from that in caspase-3-positive breast cancer cell lines,
involving activation of different caspases. In MCF-7 cells,
reduction of the mitochondrial membrane potential is
caspase independent [25].
Triple-negative breast cancer refers to a specific sub-
type of breast cancer that is characterized by lack of
expression of both estrogen and progesterone receptors
as well as HER2-neu. Clinically, triple-negative breast
cancer is more aggressive and less responsive to standard
therapies and is associated with poorer overall patient
prognosis [26,27]. To date, the therapeutic options are
very limited, leaving chemotherapy the only possible
therapy. Treatment with a GnRH-II antagonist could be a
new option for the therapy of triple-negative breast can-
cer.
Recently we showed that GnRH-II antagonists bind to
the GnRH-I receptor and are clear antagonists at the
GnRH-I receptor [18]. However, after knockdown of
GnRH-I receptor expression, GnRH-II antagonist-
induced apoptosis and apoptotic signaling was only
slightly reduced, indicating that the antitumor effects of
GnRH-II antagonists are not exclusively mediated
through the GnRH-I receptor. An additional pathway,
such as the putative GnRH-II receptor, may be responsi-
ble for GnRH-II antagonist-induced apoptosis. The
GnRH-I receptor-binding assays were carried out by
using pituitary cells and fibroblasts [18]. Therefore, we
Figure 3 Tumor volume of MCF-7 (a) and triple-negative MDA-MB-231 (b) human breast cancers xenografted into nude mice. The mice were 
treated without (control 1), with 25 nmol of GnRH-I agonist Triptorelin (control 2) or with 25 nmol of GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2, D-3Pal3,6, 
Leu8, D-Ala10]GnRH-II. Treatment was repeated every 2 days. Tumor volumes were measured on days 7, 11, 16, and 21 of treatment (MCF-7; (a) or on 
days 4, 8, 12, and 16 of treatment (MDA-MB-231; (b)). The mice were killed after 21 (MCF-7 (a)) or 16 (MDA-MB-231 (b)) days. Each experimental group 
consisted of five animals. Vertical bars represent SEM. (a) P < 0.001 versus control; (b) P < 0.05 versus control.
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because the GnRH signal transduction is dependent on
the cell context [28]. However, it cannot be ruled out that
GnRH-II antagonists-induced apoptosis is mediated
through the GnRH-I receptor. It would be very interest-
ing to know whether GnRH-II antagonist-induced activa-
tion of apoptosis and apoptotic signaling would be
abrogated after knockdown of expression of the putative
additional receptor for GnRH-II antagonists. Different
knockdown experiments, however, using GnRH-II recep-
tor antisense fragments, resulted in apoptotic cell death
(unpublished results). In addition, binding assays and
functional assays for the putative GnRH-II receptor are
not available. At present, therefore, this question cannot
be answered.
We showed the proof-of-principle of an antitumor
therapy by using the GnRH-II antagonist [Ac-D2Nal1, D-
4Cpa2, D-3Pal3,6, Leu8, D-Ala10]GnRH-II in vivo in nude
mice bearing subcutaneous xenografts of human breast
cancers. Nude mice bearing MCF-7 human breast can-
cers or MDA-MB-231 triple-negative human breast can-
cers were treated with the GnRH-II antagonists [Ac-
D2Nal1, D-4Cpa2, D-3Pal3,6, Leu8, D-Ala10]GnRH-II. The
increase of the tumor volume of the mice receiving ther-
apy with the GnRH-II antagonist was significantly lower
than that with the control animals. Toxic side effects were
not observed.
Our findings could be the basis for a further evaluation
in clinical trials. GnRH-I agonists and GnRH-I antago-
nists have been widely used in the therapy for cancer [29-
33] and endometriosis [34-36], as well as in reproductive
medicine [37-41]. Their effects are mainly due to the
downregulation of the hypothalamic-ovarian axis and the
resulting medical castration. To exclude that the antitu-
mor effects of the GnRH-II antagonist are mainly due to
an interaction with the pituitary GnRH receptors and a
subsequent reduction of ovarian estrogen production,
control groups were treated with GnRH-I agonist trip-
torelin. Because we could not observe antitumor effects
in vivo after downregulation of the hypothalamic-ovarian
axis by using the GnRH-I agonist triptorelin, the down-
regulation of the hypothalamic-ovarian axis alone cannot
be responsible for the antitumor effects of GnRH-II
antagonists. In addition, triple-negative MDA-MB-231
breast cancer cells are insensitive to estrogen deprivation.
The GnRH-II antagonist seems to affect the tumor cells
directly by inducing apoptosis.
Conclusions
We showed that the GnRH-II antagonist [Ac-D2Nal1, D-
4Cpa2, D-3Pal3,6, Leu8, D-Ala10]GnRH-II induces apop-
totic cell death in MCF-7 and triple-negative MDA-MB-
231 human breast cancer cells in vitro and in vivo. Apop-
tosis induced by the GnRH-II antagonist is mediated
through the intrinsic apoptotic pathway via the activation
of stress-induced MAPK p38 and the loss of mitochon-
drial membrane potential. GnRH-II antagonist-induced
activation of caspase-3 could be observed in MDA-MB-
231 human breast cancer cells. In addition, we showed
that knockdown of GnRH-I receptor expression only
slightly inhibited GnRH-II antagonist-induced apoptosis
and apoptotic signaling, indicating an additional pathway
mediating the effects of GnRH-II antagonists.
Thus, the GnRH-II antagonist [Ac-D2Nal1, D-4Cpa2,
D-3Pal3,6, Leu8, D-Ala10]GnRH-II seems to be a suitable
drug for an efficacious and less-toxic endocrine therapy
for breast cancers, including triple-negative breast can-
cers.
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